6-K 1 a9483x.htm DIRECTOR/PDMR SHAREHOLDING a9483x
UNITED STATES
 
SECURITIES AND EXCHANGE COMMISSION
 
Washington, D.C. 20549
 
 
FORM 6-K
 
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
 
For the month of March 2026
 
Commission File Number: 001-41411
 
Haleon plc
(Translation of registrant’s name into English)
 
Building 5, First Floor, The Heights,
Weybridge, Surrey, KT13 0NY
(Address of principal executive offices)
 
 
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:
 
 
Form 20-F
 
Form 40-F
 
 
 
EXHIBIT INDEX
 
Exhibit Number
Description
99.1
24 March 2026 - “Director/PDMR Shareholding”
 
99.1
 
Haleon plcDirector/PDMR Shareholding 
 
24 March 2026: Haleon plc (the "Company" or "Haleon") (LSE/NYSE: HLN) today announces notification and public disclosure in accordance with the requirements of The UK Market Abuse Regulation of Transactions by a Person Discharging Managerial Responsibilities ("PDMR").
 
This notification sets out the details of the vesting of Haleon share awards over ordinary shares made to a PDMR in March 2023 under the Haleon Performance Share Plan and Deferred Annual Bonus Plan and the subsequent sale of ordinary shares to meet tax liabilities.
 
On 23 March 2026, Brian McNamara, Chief Executive Officer, received the vesting of awards of Haleon ordinary shares under the Haleon Performance Share Plan and Deferred Annual Bonus Plan. Vesting under both plans included dividends accrued.
 
The award under the Performance Share Plan was conditional on continued employment and on the satisfaction of the performance conditions over the performance period ended on 31 December 2025 approved by the Remuneration Committee, which (after tax on the gross award) must be retained until the shareholding requirement is met, and in any event for Executive Directors two years after receipt.
 
 
Performance targets and levels of achievement are disclosed in the 2025 Annual Report and 20-F. The awards are subject to malus and clawback provisions.
 
 
 
Details of the issuer or emission allowance market participant
 
a)  
 
Name of the entity 
 
Haleon plc 
b)  
 
LEI  
 
549300PSB3WWEODCUP19 
 
 
Reason for the notification  
 
a)  
 
Position/status  
 
 
Chief Executive Officer
b)  
 
Initial notification /Amendment to prior notifications
 
Initial Notification 
 
 
Details of the person discharging managerial responsibilities / person closely associated ("PCA")
a)
PDMR/PCA
PDMR
 
b)  
 
Name 
 
Brian McNamara
 
 
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted  
 
a)  
 
Description of Instrument  
Share
 
 
 
Identification code  
GB00BMX86B70
 
 
 
b)  
 
Nature of the transaction  
 
 
Acquisition of Ordinary Shares in respect of the Haleon plc Performance Share Plan.
 
c)  
 
Currency, Price(s) and Volume(s)  
 
 
 
 
 
 
 
Price(s) 
Volume(s) 
 
 
 
 
Nil
1,497,695.24
 
 
 
 
 
 
d)  
 
Aggregated information  
 
 
 
- Aggregated volume 
N/A
 
 
- Price 
 
 
 
e)  
 
Date of the transaction  
 
23 March 2026
f)  
 
Place of the transaction  
 
Outside a trading venue
 
 
 
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted  
 
a)  
 
Description of Instrument  
Share
 
 
 
Identification code  
GB00BMX86B70
 
 
 
b)  
 
Nature of the transaction  
 
 
Automatic disposal of Ordinary Shares resulting from Haleon plc Performance Share Plan vesting to cover tax liabilities.
 
c)  
 
Currency, Price(s) and Volume(s)  
 
 
 
 
 
 
 
Price(s) 
Volume(s) 
 
 
 
 
£3.684419
704,974.22
 
 
 
 
 
 
d)  
 
Aggregated information  
 
 
 
- Aggregated volume 
N/A
 
 
- Price 
 
 
 
e)  
 
Date of the transaction  
 
23 March 2026
f)  
 
Place of the transaction  
 
London Stock Exchange (XLON) 
 
 
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted  
 
a)  
 
Description of Instrument  
Share
 
 
 
Identification code  
GB00BMX86B70
 
 
 
b)  
 
Nature of the transaction  
 
 
Acquisition of Ordinary Shares in respect of the Haleon plc Deferred Annual Bonus Plan.
 
c)  
 
Currency, Price(s) and Volume(s)  
 
 
 
 
 
 
 
Price(s) 
Volume(s) 
 
 
 
 
Nil
133,733.56
 
 
 
 
 
 
d)  
 
Aggregated information  
 
 
 
- Aggregated volume 
N/A
 
 
- Price 
 
 
 
e)  
 
Date of the transaction  
 
23 March 2026
f)  
 
Place of the transaction  
 
Outside a trading venue
 
 
 
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted  
 
a)  
 
Description of Instrument  
Share
 
 
 
Identification code  
GB00BMX86B70
 
 
 
b)  
 
Nature of the transaction  
 
 
Automatic disposal of Ordinary Shares resulting from Haleon plc Deferred Annual Bonus Plan vesting to cover tax liabilities.
 
c)  
 
Currency, Price(s) and Volume(s)  
 
 
 
 
 
 
 
Price(s) 
Volume(s) 
 
 
 
 
£3.684419
63,012.31
 
 
 
 
 
 
d)  
 
Aggregated information  
 
 
 
- Aggregated volume 
N/A
 
 
- Price 
 
 
 
e)  
 
Date of the transaction  
 
23 March 2026
f)  
 
Place of the transaction  
 
London Stock Exchange (XLON) 
 
 
Amanda Mellor
Company Secretary
 
About Haleon
Haleon (LSE/NYSE: HLN) is a consumer company that is solely focused on better everyday health. Our people, our brands, our research, our investment and our innovation are aimed at improving the everyday health of consumers. Our product portfolio spans six major categories - Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health and Other. Our superior brands - such as AdvilCentrumOtrivinPanadolparodontaxPolidentSensodyneTheraflu and Voltaren - are trusted by more than one billion consumers and are recommended by health professionals around the world.
 
For more information, please visit www.haleon.com
 
 
 
SIGNATURE
 
 
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
 
 
 
HALEON PLC
(Registrant)
 
Date: March 24, 2026
By:
/s/ Amanda Mellor
 
 
Name:
Amanda Mellor
 
 
Title:
Company Secretary